Redmile Group, LLC

CIK: 0001425738

Transaction Breakdown

Open Market Buys (P)12 (24.5%)

High conviction signal

Open Market Sales (S)9 (18.4%)

Position reduction

Option Exercises (M)1 (2.0%)

Derivative conversions

Awards (A)9 (18.4%)

Compensation grants

Other (G, F, J, C, D, …)18 (36.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (7)

ATTO

Attovia Therapeutics, Inc.

10% Owner

ATRA

Atara Biotherapeutics, Inc.

Director

FATE

FATE THERAPEUTICS INC

Director10% Owner

ADCT

ADC Therapeutics SA

10% Owner

STTK

Shattuck Labs, Inc.

Director10% Owner

IGMS

IGM Biosciences, Inc.

Director10% Owner

AUGX

Augmedix, Inc.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (49 total)

ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Purchase(P)
Indirect
400K shares at avg. $17.00$6.8M
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Purchase(P)
Direct
200K shares at avg. $17.00$3.4M
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Conversion(C)
Indirect
782.9K shares-
ATRA
Atara Biotherapeutics, Inc.
Jul 22, 2026
Exercise(M)
Indirect
195.2K shares-
ATRA
Atara Biotherapeutics, Inc.
Jul 22, 2026
Tax Payment(F)
Indirect
60 shares-
FATE
FATE THERAPEUTICS INC
Jun 12, 2026
Award(A)
Stock Option (Right to Buy)
Indirect
87.9K shares-
FATE
FATE THERAPEUTICS INC
Apr 20, 2026
Other(J)
Cash-settled Swaps
Direct
266.3K shares-
FATE
FATE THERAPEUTICS INC
Apr 20, 2026
Other(J)
Cash-settled Swaps
Indirect
266.3K shares-
FATE
FATE THERAPEUTICS INC
Apr 20, 2026
Other(J)
Direct
9M shares-
FATE
FATE THERAPEUTICS INC
Apr 20, 2026
Other(J)
Indirect
9M shares-
ADCT
ADC Therapeutics SA
Apr 2, 2026
Sale(S)
Direct
2.5M shares at avg. $3.28$8.3M
ADCT
ADC Therapeutics SA
Apr 2, 2026
Sale(S)
Indirect
2.6M shares at avg. $3.28$8.6M
ADCT
ADC Therapeutics SA
Apr 1, 2026
Sale(S)
Indirect
169.3K shares at avg. $3.80$643K
ADCT
ADC Therapeutics SA
Apr 1, 2026
Sale(S)
Direct
162.5K shares at avg. $3.80$617K
ADCT
ADC Therapeutics SA
Mar 31, 2026
Sale(S)
Indirect
196.2K shares at avg. $3.75$736K
ADCT
ADC Therapeutics SA
Mar 31, 2026
Sale(S)
Direct
188.4K shares at avg. $3.75$707K
ADCT
ADC Therapeutics SA
Oct 27, 2025
Purchase(P)
Pre-Funded Warrants
Direct
3.8M shares at avg. $3.90-
ADCT
ADC Therapeutics SA
Oct 27, 2025
Purchase(P)
Pre-Funded Warrants
Indirect
3.8M shares at avg. $3.90-
STTK
Shattuck Labs, Inc.
Aug 25, 2025
Award(A)
Common Warrants to Purchase Common Stock
Indirect
4.1M shares-
STTK
Shattuck Labs, Inc.
Aug 25, 2025
Award(A)
Pre-Funded Warrants to Purchase Common Stock
Indirect
4.1M shares-
IGMS
IGM Biosciences, Inc.
Aug 14, 2025
Disposition(D)
Indirect
3M shares-
STTK
Shattuck Labs, Inc.
Jul 14, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
33.2K shares-
IGMS
IGM Biosciences, Inc.
Jun 30, 2025
Award(A)
Indirect
828 shares-
ADCT
ADC Therapeutics SA
Jun 11, 2025
Purchase(P)
Pre-Funded Warrants
Direct
12.5M shares at avg. $3.43-
ADCT
ADC Therapeutics SA
Jun 11, 2025
Purchase(P)
Pre-Funded Warrants
Indirect
15.7M shares at avg. $3.43-

		Type	Shares	Price		Ownership
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Purchase(P)	400,000	$17.00	$6,800,000	Indirect
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Purchase(P)	200,000	$17.00	$3,400,000	Direct
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Conversion(C)	782,854	-	$0	Indirect
Jul 22, 2026	ATRA Atara Biotherapeutics, Inc.	Exercise(M)	195,211	-	$0	Indirect
Jul 22, 2026	ATRA Atara Biotherapeutics, Inc.	Tax Payment(F)	60	-	$0	Indirect
Jun 12, 2026	FATE FATE THERAPEUTICS INC	Award(A) Stock Option (Right to Buy)	87,900	-	-	Indirect
Apr 20, 2026	FATE FATE THERAPEUTICS INC	Other(J) Cash-settled Swaps	266,280	-	-	Direct
Apr 20, 2026	FATE FATE THERAPEUTICS INC	Other(J) Cash-settled Swaps	266,280	-	-	Indirect
Apr 20, 2026	FATE FATE THERAPEUTICS INC	Other(J)	8,977,624	-	$0	Direct
Apr 20, 2026	FATE FATE THERAPEUTICS INC	Other(J)	8,977,624	-	$0	Indirect
Apr 2, 2026	ADCT ADC Therapeutics SA	Sale(S)	2,529,491	$3.28	$8,294,201	Direct
Apr 2, 2026	ADCT ADC Therapeutics SA	Sale(S)	2,634,506	$3.28	$8,638,545	Indirect
Apr 1, 2026	ADCT ADC Therapeutics SA	Sale(S)	169,265	$3.80	$643,038	Indirect
Apr 1, 2026	ADCT ADC Therapeutics SA	Sale(S)	162,517	$3.80	$617,402	Direct
Mar 31, 2026	ADCT ADC Therapeutics SA	Sale(S)	196,229	$3.75	$736,251	Indirect
Mar 31, 2026	ADCT ADC Therapeutics SA	Sale(S)	188,407	$3.75	$706,903	Direct
Oct 27, 2025	ADCT ADC Therapeutics SA	Purchase(P) Pre-Funded Warrants	3,846,153	$3.90	-	Direct
Oct 27, 2025	ADCT ADC Therapeutics SA	Purchase(P) Pre-Funded Warrants	3,846,153	$3.90	-	Indirect
Aug 25, 2025	STTK Shattuck Labs, Inc.	Award(A) Common Warrants to Purchase Common Stock	4,097,730	-	-	Indirect
Aug 25, 2025	STTK Shattuck Labs, Inc.	Award(A) Pre-Funded Warrants to Purchase Common Stock	4,097,730	-	-	Indirect
Aug 14, 2025	IGMS IGM Biosciences, Inc.	Disposition(D)	2,964,843	-	-	Indirect
Jul 14, 2025	STTK Shattuck Labs, Inc.	Award(A) Stock Option (Right to Buy)	33,150	-	-	Indirect
Jun 30, 2025	IGMS IGM Biosciences, Inc.	Award(A)	828	-	-	Indirect
Jun 11, 2025	ADCT ADC Therapeutics SA	Purchase(P) Pre-Funded Warrants	12,465,234	$3.43	-	Direct
Jun 11, 2025	ADCT ADC Therapeutics SA	Purchase(P) Pre-Funded Warrants	15,734,267	$3.43	-	Indirect

1-25 of 49 transactions

About Redmile Group, LLC

Redmile Group, LLC (SEC CIK 0001425738) files insider reports with the SEC as 10% Owner of Attovia Therapeutics, Inc. (ATTO), Director of Atara Biotherapeutics, Inc. (ATRA) and Director of FATE THERAPEUTICS INC (FATE). Signal8 also holds filings tied to 4 other companies.

Signal8 holds 24 ownership filings by Redmile Group, LLC (2 Form 3, 22 Form 4), filed between Oct 2, 2024 and Aug 7, 2026. Those filings report 49 transactions, from Sep 30, 2024 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Redmile Group, LLC's filings is in LARKSPUR, CA.

Recent filings by Redmile Group, LLC

Aug 6, 2026: Open-market purchases of ATTO shares (2 lines, Form 4, code P).
Aug 6, 2026: Conversion of ATTO shares (Form 4, code C).
Jul 22, 2026: Option exercise of ATRA shares (Form 4, code M).
Jul 22, 2026: Tax withholding of ATRA shares (Form 4, code F).
Jun 12, 2026: Grant or award of FATE derivative securities (Form 4, code A).

Other insiders filing for Attovia Therapeutics, Inc. (ATTO)

Fu Tao, President and CEO
Chan Steven, Chief Financial Officer
WALSH COLIN, Director
GOLDMAN SACHS GROUP INC, Officer
Deep Track Biotechnology Master Fund, Ltd., 10% Owner
venBio Global Strategic Fund IV, L.P., 10% Owner

How to read Form 4 transaction codes